Your browser doesn't support javascript.
Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China.
Sun, Yamin; Wang, Min; Lin, Wenchao; Dong, Wei; Xu, Jianguo.
  • Sun Y; Research Institute of Public Health, Nankai University, Tianjin, PR China.
  • Wang M; Research Center for Functional Genomics and Biochip, Tianjin, PR China.
  • Lin W; Research Center for Functional Genomics and Biochip, Tianjin, PR China.
  • Dong W; TEDA Institute of Biological Sciences and Biotechnology, Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, Nankai University, Tianjin, PR China.
  • Xu J; Research Center for Functional Genomics and Biochip, Tianjin, PR China.
J Biosaf Biosecur ; 5(1): 14-20, 2023 Mar.
Article in English | MEDLINE | ID: covidwho-2210895
ABSTRACT
On December 7, 2022, China adjusted public health control measures, there have been widespread of SARS-CoV-2 infections in Chinese mainland. As the number of infected people increased, the mutation probability of SARS-CoV-2 is also raised. Therefore, it is of great importance to monitor SARS-CoV-2 variants and its mutations in China. In this current study, 665 SARS-CoV-2 genomes from China deposited in the public database were used to analyze the proportion of different variants; to determine the composition of variants in China across different provinces; and analyze specific mutation frequency, focusing on 12 immune escape residues. The results showed that no new mutations were generated on the 12 immune escape residues. The evolutionary analysis of the BF.7 variant circulating in China showed that there is an independent evolutionary branch with unique mutation sites, officially named BF.7.14 by PANGO. This variant may have been imported from Russia to Inner Mongolia at the end of September 2022 and continued its spread in China. The evolutionary analysis of BA.5.2 variant shows that the variant is composed of two sub-variants, named BA.5.2.48 and BA.5.2.49 by PANGO, respectively. This variant may have been imported from abroad to Beijing at the beginning of September 2022 and formed two sub-variants after domestic transmission. Finally, this study showed that current epidemic variants in China were already circulating in other countries, and there were no additional mutations on immune escape residues that could pose a threat to other countries.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Variants Language: English Journal: J Biosaf Biosecur Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Variants Language: English Journal: J Biosaf Biosecur Year: 2023 Document Type: Article